IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 39, Issue 10, 2007, Pages 637-645

  Min, C K ^a   Kim, B G ^a   Park, G ^a   Cho, Bin ^a   Oh, I H ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DILUENT; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 10;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPRESSION VECTOR; FEMALE; HEMATOPOIETIC STEM CELL; MESENCHYMAL STEM CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECIPIENT; SCORING SYSTEM; SURVIVAL; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; CELL SEPARATION; FEMALE; GENE EXPRESSION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSION; INTERLEUKIN-10; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; PHENOTYPE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 34248213189     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705644     Document Type: Article

References (44)

1. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754-2759.
2. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10: 655-668.
3. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallorso S et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day + 5 responders and no advantage for non responders receiving anti-thymocyte globulin. Blood 2006; 107: 4177-4181.
4. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
5. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
6. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003; 174: 101-109.
7. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001; 98: 2396-2402.
8. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
9. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 203; 57: 11-20.
10. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T cellproliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397.
11. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
12. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-48.
13. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
14. Le Blanc K, Frassoni F, Ball L, Uzunel M, Lanini E, Sundberg B et al. Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease. Blood 2005; 106: 1439-1441.
15. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441.
16. Min CK, Maeda Y, Lowler K, Liu C, Clouthier S, Lofthus D et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4 + and CD8 + T cellsubsets after experimental allogeneic bone marrow transplantation. Blood 2004; 104: 3393-3399.
17. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998; 101 1835-1842.
18. Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte Jr J, Crawford JM et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
19. Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433-1440.
20. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-3844.
21. Oh IH, Kang YJ, Cho B. IL-10 is a novel ligand for hematopoietic stem cell transplantation. Blood 2004; 104: 2164.
22. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Imnumol 1998; 160: 5213-5220.
23. Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8 + T cell-mediated acute graft-versus-host disease. J Clin Invest 2002; 109: 1335-1344.
24. Holler E. Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol 2002; 9: 479-484.
25. Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321-334.
26. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822.
27. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
28. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cellunresponsiveness. Blood 2005; 105 2214-2219.
29. Javazon EH, Beggs KJ, Flake AW. Mesenchymal stem cells: Paradoxes of passaging. Exp Hematol 2004; 32: 414-425.
30. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler JJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-3608.
31. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immumol 1993; 150: 4754-4765.
32. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991; 174: 1549-1555.
33. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 1993; 23: 333-337.
34. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998; 102: 1742-1748.
35. Hirayama M, Azuma E, Kumamoto T, Iwamoto S, Nashida Y, Araki M et al. Discrimination of acute graft-versus-host disease from infections by enumeration of peripheral blood interferon-gamma spot-forming cells. Transplantation 2006; 81: 632-635.
36. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR et al. Interleukin 10, a novel B cell stimulatory factor: Unresponsiveness of X chromosome-linked immuno-deficiency B cells. J Exp Med 1990; 172: 1625-1631.
37. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J Immunol 1990; 145: 4167-4173.
38. Chen WF, Zlotnik A. IL-10: A novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528-534.
39. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842-851.
40. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Narula SK, Smith SR, Roncarolo MG et al. Interleukin-10 dose-dependent regulation of CD4 + and CD8 + T cell-mediated graft-versus-host disease. Transplantation 1998; 66: 1220-1229.
41. Storb R. Bone marrow transplantation. Transplant Proc 1995; 27 2649-2652.
42. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
43. Barrett AJ. Mechanisms of the graft-versus-leukemia reaction. Stem Cells 1997; 15: 248-258.
44. Yang YG, Qi J, Wang MG, Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. Blood 2002; 99: 4207-4215.